Studies in vivo and in vitro performed by Xu Z et al. revealed that, in CRC cases, CCL19 may block angiogenesis by inhibiting tyrosine-protein kinase Met (Met)/extracellular signal regulated kinase (ERK)/Elk-1/hypoxia-inductible factor-1 alpha (HIF-1α)/VEGF-A pathway in a CCR7-dependent pattern [88]. The gene discussed is CCL19; the disease is colorectal carcinoma.